A | 在最新揭晓的第四届《福布斯亚洲》亚太区“100家值得关注企业”排行榜中，一批充满活力的初创公司和微型企业成为了投资者瞩目的焦点。 (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 
。
B | 这些企业不仅展示了他们的创新实力，还晒出了令人瞩目的支票簿——截至目前，它们已共同吸引超过20亿美元的投资。在这个风险投资资金创下七年新低的背景下，83家公司自2023年起成功募集资金，展现了它们在逆境中的坚韧与成长。图源：FACEBOOK在该排行榜中，新加坡的初创企业表现突出，共有15家公司上榜，这使得新加坡成为上榜企业数量第二多的国家，仅次于印度，但比去年的20家减少了五家。紧随其后的是中国大陆和日本，分别有10家和9家公司上榜。印度则以20家公司上榜位居榜首，去年印度共有六家企业上榜，中国大陆有11家，日本则有三家。创新是企业发展的源动力 这些上榜企业讲述了一个个稳步增长的故事，证明了成功并非一夜之间的事。而另一些公司则迅速在太空技术、生物技术和机器人技术等全球最热门的行业中崭露头角，争夺先机。
C | 这100家公司的业务组合多样，但都秉承一个共同理念：创新驱动发展。
D | 图源：FACEBOOK在今年的榜单中，新加坡在企业科技与机器人类别中有最多公司上榜，共五家，虽然比去年的九家少了四家。这些公司包括使用人工智能（AI）自动化企业财务数据管理的Bluesheets和提供浏览器网络安全插件的SquareX、用于定制搬运机器人的Botsync、为儿童创造安全数字平台的K-ID，为电商企业提供解决方案的Graas。其次是金融业，和去年一样有四家上榜，包括帮助小企业进行跨境交易的Tazapay，为电商企业提供灵活融资服务的Jenfi，提供“先付后买”服务的Fluid和HitPay。生物科技及医疗保健行业的公司数量从去年的四家减少到两家，包括专注于大脑退化检测的Neurowyzr，专注慢性疾病疗法的Mesh Bio。食品及接待业也只有一家公司上榜，即健康食品连锁企业SaladStop! Group。前沿科技企业展现更长远的发展前景 去年没有上榜的制造与能源业和航天科技业，今年分别有两家公司上榜。制造与能源业包括制作废料回收锂电池的NEU BatteryMaterials，ecoSPIRITS专注于可回收利用的玻璃瓶，而航天科技业则有研发电力推动航天引擎的Aliena。图源：FACEBOOK福布斯已经连续四年发布这个榜单，今年的上榜企业来自16个国家和地区，覆盖了企业技术与机器人、金融、制造与能源等10个行业。符合提名的公司必须满足几个条件：其总部必须位于亚太区，必须是私人所有并以盈利为目标。此外，截至今年8月7日的年营收不能超过5000万美元（约6521万新元），总融资不超过1亿美元。上榜企业必须对区域或行业有积极影响，有收入强劲增长的记录或有吸引资金的能力，拥有有潜力的商业模式或前景，以及具有说服力的卖点。总体来看，今年的榜单依旧着重于创新，从航空航天、人工智能、生物医学、健康分析到支持无银行账户民众需求的金融科技，这些上榜的企业展示了亚太区初创企业的前沿技术和创新思维。这些企业不仅代表了新加坡的创业精神，也反映了亚太区整体的创新趋势和商业潜力。
Current article:http://m9it4.michengyuraochixun.buzz/news/20260826_3659958.html
Published on:02:53:01
